Zura Bio (ZURA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Leadership and strategic focus

• Newly appointed CEO with prior involvement as founder and board member, emphasizing transition from execution to data-driven company.

• Main focus on advancing tibulizumab, a bispecific antibody targeting IL-17A and BAFF, for autoimmune inflammatory disorders.

• Two key phase II readouts expected: hidradenitis suppurativa (Q4 this year) and systemic sclerosis (first half 2027).

• Capital allocation is prioritized, with additional assets (IL-7 receptor antibody and IL-33 antibody) in early focus but not yet funded for trials.

• Future indications are under consideration, balancing orphan and broader populations, with updates expected later this year.

Clinical development and pipeline

• Tibulizumab is engineered from Eli Lilly’s tabalumab and ixekizumab, combining validated targets for enhanced efficacy.

• Phase II hidradenitis suppurativa study expanded to 225 patients, focusing on robust data quality and minimizing placebo response.

• Dosing regimen involves initial loading followed by monthly administration, with high predicted target engagement.

• Immunogenicity rates are low (<5%), attributed to strong bioengineering and balanced target affinity.

• Additional pipeline assets include crebankitug (IL-7R antibody from Pfizer) and torudokimab (IL-33 antibody from Lilly).

Scientific rationale and disease focus

• Hidradenitis suppurativa chosen due to complex, heterogeneous biology; both IL-17 and B-cell/BAFF pathways implicated.

• Recent clinical data from other B-cell targeted therapies (e.g., ianalumab, remibrutinib, iscalimab) support the approach.

• Study design excludes prior IL-17 failures but allows up to 30% TNF failures; primary endpoint is reduction in abscess and nodule count, with HiSCR 75 as a key secondary.

• Systemic sclerosis trial targets diffuse subtype with significant skin and lung involvement, using modified Rodnan skin score and AI-based HRCT for endpoints.

• Standard of care (e.g., MMF, methotrexate) is allowed if stable, ensuring real-world applicability.